Skip To Main Content
Cristina Barrenetxea on Muck Rack

Cristina Barrenetxea

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Cristina

Contact Cristina, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A phase Ib/II trial combining brentuximab vedotin with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone (BrEPEM) for older patients with untreated classical Hodgkin lymphoma: A multicentre GELTAMO trial

|
By Cecilia Carpio, Ramón García-Sanz, Izaskun Zeberio, Cristina Barrenetxea
| mtr.cool
CONFLICT OF INTEREST STATEMENT Cecilia Carpio has received consultancy fees and/or honoraria from Regeneron, BMS, Takeda, Janssen and Novartis and has participated in advisory boards for Regeneron, Takeda, BMS, Novotech and Janssen. Fátima de la Cruz-Vicente has received honoraria from Takeda, Janssen, EUSA Pharma, AbbVie, Roche and Beigene and has participated in an advisory board for Janssen, EUSA Pharma, AbbVie, Roche, Beigene and Kyowa Kirin.
Open in Who Shared Issue with article?
See all 1 articles